0
—
—
0
—
—
The TIMI Risk Score for Acute Coronary Syndromes (ACS) is a validated clinical prediction tool that estimates the 14-day risk of death, myocardial infarction, or urgent revascularization in patients presenting with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI). Developed by Antman and colleagues from the Thrombolysis In Myocardial Infarction (TIMI) clinical trial group, this score has become one of the most widely used risk assessment tools in acute cardiac care worldwide.
The TIMI Risk Score consists of seven binary variables, each worth one point: age 65 or older, three or more coronary artery disease risk factors (family history, hypertension, hypercholesterolemia, diabetes, current smoking), known coronary artery disease with 50% or greater stenosis, aspirin use in the past 7 days (reflecting aspirin-resistant disease), two or more anginal episodes in the preceding 24 hours, ST-segment deviation of 0.5mm or more on the presenting ECG, and elevated cardiac biomarkers (troponin or CK-MB). The total score ranges from 0 to 7.
The score was derived from 1,957 patients in the TIMI 11B trial and validated in 2,544 patients from the ESSENCE trial. In the derivation cohort, 14-day event rates increased progressively from 4.7% at a score of 0-1 to 40.9% at a score of 6-7. The score demonstrated consistent performance across multiple validation cohorts and has been shown to predict both short-term and long-term outcomes in ACS patients.
A key clinical application of the TIMI Risk Score is guiding the decision between conservative (medical) management and an early invasive strategy (catheterization with intent to revascularize). The TACTICS-TIMI 18 trial demonstrated that patients with higher TIMI scores (3 or above) derived significantly greater benefit from an early invasive approach compared to conservative management, while lower-risk patients (TIMI score 0-2) had similar outcomes with either strategy. This finding has been incorporated into ACC/AHA guidelines for the management of UA/NSTEMI.
The inclusion of aspirin use as a risk factor reflects the clinical observation that patients who develop ACS despite aspirin therapy have more aggressive disease biology and higher event rates. Similarly, recurrent anginal episodes within 24 hours suggest unstable plaque pathophysiology with ongoing ischemia. ST-segment deviation and elevated cardiac markers provide objective evidence of myocardial ischemia and necrosis, respectively, and are the strongest individual predictors within the score.
While the TIMI score remains valuable, its limitations should be understood. It was developed in a clinical trial population that may not fully represent all emergency department chest pain patients. The HEART score may be more appropriate for initial risk stratification of undifferentiated chest pain in the ED, while the TIMI score is best applied after a clinical diagnosis of UA/NSTEMI has been established. The GRACE score provides an alternative and potentially more accurate risk prediction in confirmed ACS. Using these tools in combination with clinical judgment ensures optimal patient management.
The TIMI Risk Score sums 7 binary risk factors (each worth 1 point): age >= 65, >= 3 CAD risk factors, known CAD with >= 50% stenosis, aspirin use in past 7 days, >= 2 anginal episodes in 24 hours, ST deviation >= 0.5mm, and elevated cardiac markers. The total score (0-7) maps to 14-day risk of death, MI, or urgent revascularization, ranging from 4.7% (score 0-1) to 40.9% (score 6-7).
Score 0-2: Low risk (4.7-8.3% event rate). Conservative medical management is generally appropriate with consideration for non-invasive testing. Score 3-4: Moderate-high risk (13.2-19.9%). Early invasive strategy shows benefit in clinical trials. Score 5-7: High risk (26.2-40.9%). Urgent invasive strategy is recommended with cardiology consultation. Higher scores correlate with greater benefit from early invasive management.
Inputs
Results
Two risk factors present. Conservative management with serial troponins and stress testing is reasonable.
Inputs
Results
Maximum score with all risk factors present. Approximately 41% risk of MACE at 14 days requires urgent catheterization.
TIMI stands for Thrombolysis In Myocardial Infarction, a research group based at Brigham and Women's Hospital and Harvard Medical School. The TIMI group has conducted numerous landmark clinical trials in cardiovascular medicine and developed several widely-used risk scores and treatment protocols.
The TIMI Risk Score is best applied in patients with confirmed or strongly suspected unstable angina or NSTEMI. It guides decisions about conservative versus invasive management strategies. For initial risk stratification of undifferentiated chest pain in the ED, the HEART score may be more appropriate.
Aspirin use in the preceding 7 days as a risk factor identifies patients who developed ACS despite antiplatelet therapy. This suggests more aggressive thrombotic disease, aspirin resistance, or higher plaque burden. These patients have been shown to have worse outcomes in clinical studies.
The standard risk factors counted are: family history of premature coronary artery disease, hypertension, hypercholesterolemia, diabetes mellitus, and current active smoking. Having 3 or more of these factors scores 1 point in the TIMI Risk Score.
TACTICS-TIMI 18 demonstrated that patients with TIMI scores of 3 or higher benefit significantly from an early invasive strategy (catheterization within 24-48 hours). Patients with scores of 0-2 had similar outcomes with conservative or invasive management, allowing a conservative initial approach with subsequent testing.
TIMI uses binary variables for simplicity, while GRACE uses continuous variables (age, heart rate, blood pressure, creatinine, Killip class) for potentially greater precision. GRACE may provide better discrimination for in-hospital and 6-month mortality prediction. Both are valid; local protocols typically specify which to use.
This TIMI Risk Score is specifically for UA/NSTEMI. A separate TIMI Risk Score for STEMI exists, which uses different variables including age, vital signs, Killip class, weight, anterior MI location, time to treatment, and history of diabetes, hypertension, or angina.
Elevated cardiac markers typically means troponin (I or T) or CK-MB above the 99th percentile of the upper reference limit. High-sensitivity troponin assays have different cutoff values than conventional assays. Any elevation above the assay-specific normal range qualifies for this criterion.
Yes, the TIMI Risk Score has been validated in both men and women. However, women with ACS may present with more atypical symptoms, potentially affecting the History component in risk assessment. The objective components (ECG, troponin, known CAD) maintain their predictive value regardless of sex.
ST deviation of 0.5mm or more indicates active myocardial ischemia and is one of the strongest individual predictors of adverse outcomes in UA/NSTEMI. It identifies high-risk plaque instability and often prompts consideration of an early invasive strategy regardless of the overall TIMI score.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
Framingham Risk Score
Cardiology Calculators - Cardiovascular Risk Calculators
CHA₂DS₂-VASc Score
Cardiology Calculators - Cardiovascular Risk Calculators
HAS-BLED Score
Cardiology Calculators - Cardiovascular Risk Calculators
CHADS2 Score
Cardiology Calculators - Cardiovascular Risk Calculators
HEART Score
Cardiology Calculators - Cardiovascular Risk Calculators
GRACE Score
Cardiology Calculators - Cardiovascular Risk Calculators
